

Publications:

1. Gawienowski, A.M. and **Chatterjee, D.**
Effect of prostaglandin inhibitor on the uterotrophic response of estradiol and gibberellic acid.
Life Sciences, 27: 15, 1393, 1980.
2. Gawienowski, A.M., **Chatterjee, D.**, Anderson, P.J., Grant, W.M., and Epstein, D.L.
Effect of d-9-tetrahydrocannabinol on monamine oxidase activity in bovine eye tissues, *in vitro*.
Invest. Ophthalmol. and Vision Science, 22:4, 482, 1982.
3. **Chatterjee, D.**, Mendelsohn, A.M., Shank, P.R. and Savarese, T.M.
Reversible suppression of *c-myc* expression in a human colon carcinoma cell line by the anticancer agent N-methylformamide.
Cancer Research 49: 3910, 1989.
4. **Chatterjee, D.** and Savarese, T.M.
Post-transcriptional regulation of *c-myc* expression and growth inhibition by recombinant human β -interferon-ser¹⁷ in a human colon carcinoma cell line.
Cancer Chemother. Pharmacol. 30: 12-16, 1992.
5. Teicher, B.A., **Chatterjee, D.**, Liu, J.T., Holden, S.A. and Ara, G.
Protection of bone marrow CFU-GM in mice bearing *in vivo* alkylating resistant EMT-6 tumors.
Cancer Chemother. Pharmacol. 32: 315-319, 1993.
6. Han, Z., **Chatterjee, D.** and Wyche, J.H.
Proliferation of nontransformed cells is inhibited by adenosine metabolite of but not by parental 8-Cl-cAMP.
J. Pharm. and Exp. Therap. 265: 790-794, 1993.
7. Han, Z., **Chatterjee, D.**, Bakker, A. and Wyche J.H.
Positive and negative regulation of IGF-II mRNA in cultured rat cells by chicken serum.
Mol. Cell. Endocrinol. 99: 293-300, 1994.
8. **Chatterjee, D.**, Liu, J.T., Northery, D. and Teicher, B.A.
Molecular characterization of the *in vivo* alkylating agent resistant murine EMT-6 mammary carcinoma tumors.
Cancer Chemother. Pharmacol. 35 (5), 423-431, 1995.
9. Han, Z., **Chatterjee, D.**, He, D-M., Early, J., Pantazis, P., Wyche, J.H. and Hendrickson, E.A.
Evidence for a G2-checkpoint in p53-independent apoptosis induction by x-irradiation.

- Mol. Cell. Biol. 15: 5849-5857, 1995.
10. Pantazis, P., DeJesus, A., Early, J., Rodriguez, R., **Chatterjee, D.**, Wyche, J.H. and Giovenella, B.
Development of human leukemia U-937 cell sublines resistant to doxorubicin: Induction of differentiation and altered sensitivities to topoisomerase-directed drugs. *Anticancer Res.* 15: 1873-1882, 1995.
 11. Han, Z., **Chatterjee, D.**, Early, J., Pantazis, P., Hendrickson, E.A. and Wyche, J.H.
Isolation and characterization of an apoptosis-resistant mutant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-x_L. *Cancer Res.* 56: 1621-1628, 1996.
 12. Pantazis, P., **Chatterjee, D.**, Han, Z., Wyche, J.H., DeJesus, A. and Giovenella, B.
Monocytic differentiation and synthesis of proteins associated with apoptosis in human leukemia U937 cells acquiring resistance to vincristine. *Eur. J. Haematol.* 57: 779-786, 1996.
 13. **Chatterjee, D.**, Wyche, J.H. and Pantazis, P. induction of apoptosis in malignant and camptothecin-resistant human cells. *Ann. N.Y. Acad. Sci.* 803: 143-156, 1996.
 14. Pantazis, P., **Chatterjee, D.**, Wyche, J.H., DeJesus, A., Early, J., Plaschke, S. and Giovenella, B.
9-Nitrocamptothecin-induced toxicity in human prostate carcinoma cells *in vivo* and *in vitro* does not correlate with apoptosis-associated proteins. *J. Exptl. Therap. & Oncology.* 1: 322-333, 1996.
 15. **Chatterjee, D.**, Han, Z., Mendoza, J., Goodglick, L., Hendrickson, E.A., Pantazis, P., and Wyche, J.H.
Monocytic differentiation and the survival of HL-60 promyelocytic leukemia cells is correlated with the induction of Bcl-x_L. *Cell Growth and Diff.* 8: 1083-1089, 1997.
 16. Dawicki, D.D., **Chatterjee, D.**, Wyche, J.H. and Rounds, S.
Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells. *Am. J. Physiol.* 273: 1485-1489, 1997.
 17. Pantazis, P., Han, Z., **Chatterjee, D.** and Wyche, J.H. Water insoluble camptothecins analogs as potential antiviral drugs. *Biomed Sci.*, 6: 1-7, 1999.
 18. Cao, Z., Han, Z., **Chatterjee, D.**, Wyche, J.H. and Pantazis, P. Propionate and butyrate esters of camptothecin and 9-nitrocamptothecin as antileukemia prodrugs *in vitro*. *Eur. J. Haematol.*, 62: 246-255, 1999.

19. Pantazis, P., **Chatterjee, D.**, Han, Z. and Wyche, J.H. Modulation of 9-nitrocamptothecin-induced apoptosis in human leukemia HL-60 cells. *Anti-Cancer Drugs*, 10: 317-322, 1999.
20. Pantazis, P., **Chatterjee, D.**, Han, Z. and Wyche J.H. Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin *in vitro*. *Neoplasia*, 1: 1-10, 1999.
21. *Bremner, T.A., ***Chatterjee, D.**, Han, Z., Tsan, M-F and Wyche, J.H. THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells. *Leukemia Res.* 23: 865-870, 1999.
***equivalent contribution**
22. **Chatterjee, D.**, Li, G., Hendrickson, E.A., Bremner, T.A. and Wyche, J.H. Susceptibility to apoptosis is restored in human leukemia HCW-2 cells following induction and stabilization of the apoptotic effector Bak. *Oncogene*, 19: 4108-4116, 2000.
23. **Chatterjee, D.**, Romero, D.P., Wyche, J.H. and Pantazis., P. Telomerase activity, Myc and Bcl-2: Possible indicators of effective therapy of prostate cancer with 9-nitrocamptothecin. *Anticancer Research*, 20: 2885-2890, 2000.
24. **Chatterjee, D.**, Wyche, J.H. and Pantazis, P. Specific alterations in the cell cycle regulators, cyclin B1 and cyclin-dependent kinase cdc2, upon 9-nitrocamptothecin-induced regression of DU145 human prostate tumor and apoptosis of DU145 cells. *Anticancer Research*, 20: 4477-4482, 2000.
25. Urasaki, Y., Laco, G.S., Pourquier, Y.P., Takebayashi, K., Kohlhagen, G., Gioffre, C., **Chatterjee, D.**, Pantazis, P. and Pommier, Y. Characterization of a novel topoisomerase I mutation from a camptothecin resistant prostate cancer cell line. *Cancer Res.* 61: 1964-1969, 2001.
26. **Chatterjee, D.**, Schmitz, I., Yeung, K., Krueger, A., Kirchoff, S., Krammer, P.H., Peter, M.E., Wyche, J.H. and Pantazis, P. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIPshort. *Cancer Res.*, 61: 7148-7154, 2001.

27. Yeung, K.C, Rose, D.W., Dhillon, A., Yaros, D., Gustafsson, M., **Chatterjee, D.**, McFerran, B., Wyche, J., Kolch, W. and Sedivy, J.M. RKIP interacts with NIK and TAK1 and inhibits NF- κ B activation. *Mol. Cell. Biol.*, 21: 7207-7217, 2001.
28. Mukhopadhyay, A., Bueso-Ramos, C., **Chatterjee, D.**, Pantazis, P. and Aggarwal, B.B. Curcumin downregulates cell survival mechanism in human prostate cancer cell lines. *Oncogene*, 20: 7597-7609, 2001.
29. Ribizzi, I., Danowski, J.W., Goulette, F.A., Akhtar, M.S., **Chatterjee, D.** and Calabresi, P. Taurodine: Preclinical Evaluation of a Novel, Highly Selective, Agent for Bone Marrow Purging. *Bone Marrow Transplantation*, 29: 313-319, 2002.
30. **Chatterjee, D.**, Roy, R., Braastad, C., Mott, S., Sun, Y., Mukhopadhyay, A., Aggarwal, B., Darnowski, J., Pantazis, P., Wyche, J.H., Sedivy, J.M. and Yeung, K. RKIP Sensitizes Prostate and Breast Cancer Cells to Drug-Induced Apoptosis. *J. Biol. Chem*, 279, 17515-17523, 2004.
31. **Chatterjee, D.**, Goldman, M., Braastad, C., Darnowski, J., Wyche, J.H., Pantazis, P. and Goodglick, L. The Role of 14-3-3 ζ Expression in Resistance of Prostate Cancer Cells to 9-Nitrocamptothecin. *Int. J. Oncol*, 25, 503-509, 2004.
32. Darnowski, J.W., Goulette, F.A., Cousens, L.P., **Chatterjee, D.** and Calabresi, P. Mechanistic and antineoplastic evaluation of Taurodine in the DU145 model of human prostate cancer. *Cancer Chemother. Pharmacol.*, 54, 249-258, 2004.
33. Odabaei, G., **Chatterjee, D.**, Jazirehi, A.R., Goodglick, L., Yeung, K. and Bonavida, B. Raf-1 Kinase Inhibitor Protein (RKIP): Structure, Function, Regulation of Cell Signaling and Pivotal Role in Apoptosis. *Adv. Cancer Res.* 91, 169-200, 2004.
34. Jazirehi, A.R., **Chatterjee, D.**, Odabaei, G., Vega, M.I., Goodglick, L. and Bonavida, B. Rituximab triggers RKIP expression and inhibits MAPKs ERK1/2 and AP-1 activation in non-Hodgkins Lymphoma B-cells: Role in down-regulation of Bcl-x_L expression. *Cancer Res.*, 64, 7117-7126, 2004.
35. Yuan, P. Z., Guan, A. Y., **Chatterjee D.**, and Chin, Y.E. Reversible acetylation of a single lysine residue within the C-terminal region of STAT3 regulates STAT3 dimerization. *Science*, 307, 269-273, 2005.
36. Darnowski, J.W., Goulette, F.A., Guan, Y., **Chatterjee, D.**, Cousens, L.P. and Chin, Y.E. STAT3 cleavage by caspases: Impact on full-length STAT3 expression, fragment formation and transcriptional activity. Submitted to *J. Biol. Chem.*, 3/2006

37. **Chatterjee, D.,*** Sabo, E., and Resnick, M.B. The prognostic role of RKIP and STAT3 in gastric adenocarcinoma. Submitted to Clin. Cancer Res., 4/06.
* Corresponding author.

Publications in Preparation.

1. **Chatterjee, D.,** Braastad, C., Goulette, F., Mott, S., Earl, T., Calabresi, P. and Darnowski, J. Stat 3 expression is down-regulated during CD95-triggered apoptosis.
To be Submitted to Cancer Res. 5/2006.
2. Sartore-Bianchi, A., Nicci, L., Darnowski, J., Calabresi, P, and **Chatterjee, D.,.** Modulation of gimatecan-triggered apoptosis by Raf kinase inhibitory protein in HT29 colon and REN mesothelioma models of human neoplasms.
To be Submitted to Clin. Cancer Res. 4/2006.